Code Biotherapeutics, a Greater Philadelphia, PA-based biotechnology company advancing targeted non-viral delivery of genetic medicines, raised $75M in Series A funding.
The round was led by Northpond Ventures with participation from Amgen Ventures, Hatteras Venture Partners, UCB Ventures, New Enterprise Associates, 4BIO Capital, CureDuchenne Ventures, JDRF T1D Fund, UPMC Enterprises, and Takeda Ventures. As part of the financing, Diana Bernstein, Ph.D., Vice President at Northpond Ventures, will join Code Bio’s board of directors.
Led by CEO Brian P. McVeigh, Code Bio is a biotechnology company advancing genetic medicines to treat and potentially cure serious and life-threatening genetic diseases. By leveraging its novel non-viral multivalent synthetic DNA delivery platform, 3DNA®, Code Bio’s approach can overcome multiple challenges inherent with viral-based delivery approaches, including immunogenicity, size and delivery limitations, inability to re-dose and manufacturing complexity. The company is advancing an internal pipeline of therapies focused on serious and life-threatening diseases while also developing multiple collaborative partnerships to take forward additional programs in both rare and prevalent diseases.
The company intends to use the funds to advance its two lead programs in DMD and T1D toward IND-enabling studies, expand its pipeline and platform applications, and expand its manufacturing and operations.
